Adjusting Treatment Strategies Using Circulating Tumor Cells: Preliminary Results on Metastatic Colorectal Cancer

Area of Science:

• Oncology
• Molecular Diagnostics
• Clinical Research

Background:

• Metastatic colorectal cancer (mCRC) presents challenges in selecting effective second-line treatments after first-line therapy failure.
• Circulating tumor cells (CTCs) offer a potential avenue for personalized treatment strategies.

Purpose of the Study:

• To evaluate the efficacy of using circulating tumor cells (CTCs) to guide second-line treatment selection in patients with metastatic colorectal cancer (mCRC).
• To compare the overall survival (OS) of mCRC patients receiving CTC-guided treatment versus those receiving best supportive care (BSC).

Main Methods:

• CTCs were isolated from 21 mCRC patients with ineffective first-line treatments.
• Chemo-sensitivity and viability assays were performed on isolated CTCs to determine optimal second-line chemotherapeutic drugs.
• Statistical analysis, including specialized tests for small datasets and complex survival patterns, compared OS between the CTC-guided treatment group and a BSC control group (n=12), as well as with meta-analyzed BSC data.

Main Results:

• The median overall survival (mOS) for the CTC-guided treatment group was 9 months, significantly longer than the mOS of approximately 5 months in the BSC group.
• Meta-analysis of BSC data corroborated the control group's mOS at 5.15 months.
• The observed survival benefit was statistically significant, particularly for central and late hazard rates.

Conclusions:

• Treatment selection based on in vitro CTC response can prolong mOS in mCRC patients compared to BSC.
• CTC analysis demonstrates a beneficial role in predicting treatment response for mCRC patients.
• This approach supports personalized medicine strategies in advanced colorectal cancer.